• Home
  • Sector News
    • Technology
    • Energy
    • Financial Services
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report

Subscribe to stay informed!

Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

What's Hot

4 Major Changes Recommended by Wall Street Analysts: Coinbase Positively Soars While Advance Auto Parts Is Struggling

June 4, 2023

Academy Sports and Outdoors (ASO) announces regular quarterly dividend of $0.09 per share

June 4, 2023

Page Industries (NSE:PAGEIND) Price Target Reduced by 7.67% to 39,341.08

June 4, 2023
Telegram RSS
  • Government
  • Press Releases
  • Stock Market
  • Top Stories
  • Trading Insights
  • Trending
Telegram RSS
Virtus Junxit EquitiesVirtus Junxit Equities
  • Home
  • Sector News
    1. Technology
    2. Energy
    3. Financial Services
    4. View All

    Former Amazon Employee Reveals the Reason Behind Layoffs in Large Tech Companies

    June 3, 2023

    Bad Bunny’s Secret: Taking Breaks from Social Media Helps Him Feel Better

    June 3, 2023

    Vintage 2008 Video Shows Musk Presenting SpaceX’s Vision

    June 3, 2023

    Cathie Wood reduced her stake in Microsoft but increased holdings in PagerDuty and Ginkgo Bioworks

    June 3, 2023

    The Corn & Ethanol Report: Anticipating the Drought Monitor

    June 2, 2023

    Natural Gas Prices Increase as Risk Assets Rise

    June 2, 2023

    Crude Oil Prices Rise Prior to OPEC+ Meeting

    June 2, 2023

    Predicting Corn, Soybean, and Wheat Prices for June

    June 2, 2023

    ‘Fearless’ Taylor Swift Passes Madonna On Richest Self-Made Women List — Here’s Who Else The ‘All Too Well’ Singer Ranks Ahead Of – Live Nation Entertainment (NYSE:LYV)

    June 3, 2023

    Don’t let investment jargon intimidate you!

    June 3, 2023

    Grain Market Continues to be Volatile Ahead of Weekend – Corn, Soybeans, and Wheat Prices Being Closely Monitored

    June 2, 2023

    Chevron’s Attracts Investors Looking for Value and Short-Term Gains by Selling Out-of-the-Money Puts

    June 2, 2023

    4 Major Changes Recommended by Wall Street Analysts: Coinbase Positively Soars While Advance Auto Parts Is Struggling

    June 4, 2023

    Academy Sports and Outdoors (ASO) announces regular quarterly dividend of $0.09 per share

    June 4, 2023

    Page Industries (NSE:PAGEIND) Price Target Reduced by 7.67% to 39,341.08

    June 4, 2023

    Prime Minister’s Schedule for Sunday, June 4, 2023

    June 4, 2023
  • Opinion and Analysis
    • Market Overview
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Investment Idea
    • Stock Market
      • Opinion
      • Technical Analysis
      • Fundamental Analysis
      • Stock Pick
  • Virtus Report
Get Access
Virtus Junxit EquitiesVirtus Junxit Equities
Home»Stock Market»Revolutionary Anxiety Treatment: Cybin’s Proprietary DMT Compound Shows Clinical Progress within Two Minutes (AMEX:CYBN)
Stock Market

Revolutionary Anxiety Treatment: Cybin’s Proprietary DMT Compound Shows Clinical Progress within Two Minutes (AMEX:CYBN)

JamesBy JamesMay 24, 2023Updated:May 24, 2023No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email

Canadian clinical-stage psychedelics company Cybin Inc. (CYBN) announced the dosing of its proprietary deuterated DMT molecule, CYB004, on the first group of participants in an ongoing three-part Phase 1 trial on the intravenous administration of DMT and CYB004 in healthy volunteers.

CYB004, Cybin’s promising psychedelic treatment for Generalized Anxiety Disorder (GAD), exhibits robust effects within two minutes of administration, reaching a peak at around thirteen minutes. No safety concerns were reported.

Part 3 (C) of the Phase 1 trial evaluates IV bolus plus infusion regimens of CYB004 on up to two cohorts with the data from these cohorts expected to construct a comprehensive PK/PD model toward determining optimal dosing and formulation for future trials on the proprietary drug, thus advancing Cybin’s program evaluating the CYB004 drug.

The readout of the Phase 1 trial’s safety and efficacy data is expected to be released in the third quarter of 2023.

Doug Drysdale, Cybin’s CEO, called the first-in-human dosing of CYB004, “an enormous step forward” in the clinical advancement of Cybin’s program evaluating the drug for GAD treatment. Drysdale added that the inclusion of CYB004 dosing in the Phase 1 stage accelerates Cybin’s understanding of the drug’s profile, validating its advantages for humans sooner than anticipated.

More on the Trial and CYB004

The Phase 1 trial takes place at the Centre for Human Drug Research in the Netherlands. The three-part study design evaluates escalating doses of DMT and CYB004 in healthy volunteers, assessing safety, pharmacokinetics (PK), and pharmacodynamics (PD) of both compounds.

CYB004 is a novel deuterated DMT molecule, designed to provide bioavailability improvements over existing psychedelics and offer less invasive and more convenient dosing methods. Under a U.S. patent, CYB004 is being explored as a potential treatment for GAD, either with or without Major Depressive Disorder (MDD).

Besides CYB004, Cybin’s pipeline includes CYB003, a deuterated psilocybin analog for treating MDD, for which the company will present additional topline efficacy data later this year.

Image by Reimund Bertrams from Pixabay

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
Previous ArticleAvance Clinical Supports Global Health Summit for Faster Access to Life-Changing Therapies
Next Article GeoVax’s Next-Generation COVID-19 Vaccine Shows Positive Results in Single Dose – Geovax Labs (NASDAQ:GOVX)
James

    Related Posts

    Page Industries (NSE:PAGEIND) Price Target Reduced by 7.67% to 39,341.08

    June 4, 2023By James0

    3M India (NSE:3MINDIA) Price Target Increased by 6.39% to 29,733.00

    June 4, 2023By James0

    DRAEGERWERK VZO O.N. (FWB:DRW3) Price Target Reduced by 6.64% to 53.33

    June 4, 2023By James0

    Leave A Reply Cancel Reply

    Our Picks

    Prime Minister’s Schedule for Sunday, June 4, 2023

    June 4, 2023

    Apareció Foundation’s Felix Magazine Launches New Issue Focusing on Wellness & Beauty, Featuring Sam Asghari

    June 4, 2023

    Bridging the Information Gap in Healthcare

    June 4, 2023

    SBI Launches Countrywide Search for Companies to Create Custom Board Games

    June 4, 2023
    Stay In Touch
    • Facebook
    • Twitter
    • Pinterest
    • Instagram
    • YouTube
    • Vimeo
    Don't Miss

    Academy Sports and Outdoors (ASO) announces regular quarterly dividend of $0.09 per share

    Trending June 4, 2023

    Academy Sports and Outdoors has declared a regular quarterly dividend of $0.09 per share ($0.36 annualized) on June 1, 2023. Previously, the company paid the same amount. If you want to qualify for the dividend, you must purchase shares before the ex-dividend date of June 14, 2023. Shareholders of record…

    Page Industries (NSE:PAGEIND) Price Target Reduced by 7.67% to 39,341.08

    June 4, 2023

    Virgin Galactic May Not Be the Best Bet for Your Investment Portfolio

    June 4, 2023

    3M India (NSE:3MINDIA) Price Target Increased by 6.39% to 29,733.00

    June 4, 2023
    FEATURED INSIGHTS​

    Virtus Junxit Equity Report: Loop Media, Inc. (AMEX: LPTV)

    May 31, 2023

    Virtus Junxit Equity Research: Hillstream BioPharma, Inc. (NASDAQ: HILS)

    May 18, 2023

    NeuroOne Medical NMTC Extreme Potential in Medical Tech

    May 14, 2023

    EZFill Holdings (EZFL) – An In-Depth Analysis of the Company’s Market Dynamics, Financials, and Upcoming Catalysts

    May 8, 2023

    Subscribe to stay informed!

    Discover hidden stock market gems and stay up to date with our weekly email newsletter and individual stock ideas

    Telegram RSS
    • Home
    • Privacy Policy
    • Disclaimer
    • Virtus Report
    • Get Access
    © 2023 Virtus Junxit LLC

    Type above and press Enter to search. Press Esc to cancel.